PYC Share PerformanceMore
|52 week high||4.9000 28/04/16|
|52 week low||1.2050 28/02/17|
|52 week change||-2.2250 (-63.57%)|
|4 week volume||10,341,943 02/03/17|
Latest News« previous» nextMore
24/03/2017 - 15:05 StockMarketWire
Physiomics has reported an operating loss of 263,509 for the six month period ended 31 December, compared to a restated lo...
24/03/2017 - 12:15 RNS
RNS Number: 4688A Physiomics PLC 24 March 2017 Physiomics Plc ("Physiomics" or "the Company") Interim Results Statement for the six month period ended 31 December 2016 Oxford, UK, 24 March 2017: The Board of Physiomics Plc (AIM: PYC), a UK-based systems biology company, today announces its financial results for the six months ended 31 December 2...
11/01/2017 - 08:51 StockMarketWire
Physiomics anticipates that in H1 of its current financial year revenues will be broadly in line with the comparable period...
11/01/2017 - 08:00 RNS
RNS Number: 8389T Physiomics PLC 11 January 2017 Physiomics plc ("Physiomics") or ("the Company") Company Update Physiomics plc (AIM: PYC) is pleased to announce that it is making good progress towards the strategic objectives announced in its most recent full year results (RNS 27 th October 2016 and subsequent printed annual report circulated to shareho...
06/01/2017 - 08:12 StockMarketWire
Physiomics confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibility Stu...
06/01/2017 - 08:00 RNS
RNS Number: 4882T Physiomics PLC 06 January 2017 6 th January 2017 Physiomics plc ("Physiomics") or ("the Company") Confirmation of Award of Innovate UK Grant Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to confirm that is has been awarded the Innovate UK grant as part of its Biomedical Catalyst 2016 Feasibili...
22/12/2016 - 18:45 StockMarketWire
Dr James Millen, Chief Executive Officer, bought 200,000 shares in the company on the 22nd December 2016 at a price of...
22/12/2016 - 16:31 RNS
RNS Number: 6506S Physiomics PLC 22 December 2016 Physiomics plc ("Physiomics" or the "Company") Director Dealing The Company announces that it received notice today that Dr Jim Millen, the Company's CEO, has purchased a total of 200,000 ordinary shares in the Company at a price of 2.5p per share, being the most recent placing price, as announced on 2...
|Dividend yield||0 %|
Equity Research (PYC)
The computational systems biology services company whose core technology, Virtual Tumour, predicts the effects of combination chemotherapy in pre-clinical and clinical settings and helps its clients...
The computational systems biology services Company applying simulations of cell behaviour to drug development recently provided an update. It declared good progress on its strategic objectives...
Following the decision not to proceed with the acquisition of oncology therapeutics Company BioMoti, Physiomics is now 100% focused on growing the revenues and creating a path to profitability in the...
Latest discussion posts More
“proposed for the 16th December”▼
“get in.sar on the move.could be news soon.gla”▼
Codes & Symbols
|Symbols||PYC, LSE:PYC, PYC.L, PYC:LN, LON:PYC, XLON:PYC|